Zobrazeno 1 - 10
of 110
pro vyhledávání: '"Wojciech Jurczak"'
Autor:
Michael L, Wang, Wojciech, Jurczak, Mats, Jerkeman, Judith, Trotman, Pier L, Zinzani, David, Belada, Carola, Boccomini, Ian W, Flinn, Pratyush, Giri, Andre, Goy, Paul A, Hamlin, Olivier, Hermine, José-Ángel, Hernández-Rivas, Xiaonan, Hong, Seok Jin, Kim, David, Lewis, Yuko, Mishima, Muhit, Özcan, Guilherme F, Perini, Christopher, Pocock, Yuqin, Song, Stephen E, Spurgeon, John M, Storring, Jan, Walewski, Jun, Zhu, Rui, Qin, Todd, Henninger, Sanjay, Deshpande, Angela, Howes, Steven, Le Gouill, Martin, Dreyling, Joseph C, Gardiner
Publikováno v:
New England Journal of Medicine. 386:2482-2494
Ibrutinib, a Bruton's tyrosine kinase inhibitor, may have clinical benefit when administered in combination with bendamustine and rituximab and followed by rituximab maintenance therapy in older patients with untreated mantle-cell lymphoma.We randoml
Autor:
Peter Hillmen, Barbara Eichhorst, Jennifer R. Brown, Nicole Lamanna, Susan M. O'Brien, Constantine S. Tam, Lugui Qiu, Maciej Kazmierczak, Keshu Zhou, Martin Šimkovič, Jiří Mayer, Amanda Gillespie-Twardy, Mazyar Shadman, Alessandra Ferrajoli, Peter S. Ganly, Robert Weinkove, Sebastian Grosicki, Andrzej Mital, Tadeusz Robak, Anders Österborg, Habte A. Yimer, Tommi Salmi, Meng Ji, Jessica Yecies, Adam Idoine, Kenneth Wu, Jane Huang, Wojciech Jurczak
Publikováno v:
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, vol 41, iss 5
PURPOSE Zanubrutinib is a potent, irreversible next-generation Bruton tyrosine kinase (BTK) inhibitor designed to maximize BTK occupancy and minimize off-target kinase inhibition. We hypothesized that complete/sustained BTK occupancy may improve effi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::cebead271e6234bf0b9f19719ee31aa4
https://ruj.uj.edu.pl/xmlui/handle/item/305371
https://ruj.uj.edu.pl/xmlui/handle/item/305371
Autor:
Junji Suzumiya, Seok-Goo Cho, Keum Young Ahn, Marek Trneny, Eduardo Yanez Ruiz, Christian Buske, Leslie Popplewell, Jose Mario Mariz, Michinori Ogura, Larry W. Kwak, Olga Samoilova, Tobias F. Menne, Hideyuki Nakazawa, Jin Seok Kim, Edvard Zhavrid, Gayane Tumyan, Nikolai Ilyin, Sunghyun Kim, Sang-Joon Lee, Wojciech Jurczak, Won Seog Kim, Juan-Manuel Sancho, A. Martínez
Publikováno v:
Clinical Lymphoma Myeloma & Leukemia
r-IGTP. Repositorio Institucional de Producción Científica del Instituto de Investigación Germans Trias i Pujol
instname
r-IGTP. Repositorio Institucional de Producción Científica del Instituto de Investigación Germans Trias i Pujol
instname
INTRODUCTION: This double-blind, parallel-group, active-controlled phase III trial (NCT02260804) assessed CT-P10 and rituximab safety and efficacy in patients with previously untreated low-tumor-burden follicular lymphoma (LTBFL), including after a s
Autor:
Frederic Peyrade, Graham P. Collins, Yihua Lee, Jutta K. Neuenburg, Michael Wang, Robert T. Chen, Geoffrey Chong, Karl Eckert, Constantine S. Tam, Radhakrishnan Ramchandren, Lionel Karlin, Ka Lung Wu, Mark Bishton, Paul Eliadis, Wojciech Jurczak
Publikováno v:
Journal of Hematology & Oncology, Vol 14, Iss 1, Pp 1-8 (2021)
Journal of Hematology & Oncology
Journal of Hematology & Oncology
Ibrutinib plus venetoclax, given with an ibrutinib lead-in, has shown encouraging clinical activity in early phase studies in mantle cell lymphoma (MCL). The ongoing phase 3 SYMPATICO study evaluates the safety and efficacy of concurrently administer
Autor:
KeumYoung Ahn, Mariana Vasilica, Christian Buske, Rajnish Nagarkar, Edvard Zhavrid, Aliaksandr Prokharau, Sung-Hyun Kim, Juan-Manuel Sancho, Michinori Ogura, Won Seog Kim, Wojciech Jurczak, Jose Angel Hernandez-Rivas, Jin Seok Kim, Sang Joon Lee, Larry W. Kwak
Publikováno v:
Blood Adv
Rituximab biosimilars are a cornerstone of treatment of advanced-stage follicular lymphoma (FL). This double-blind, parallel-group, phase 3 trial randomized (1:1) adults (≥18 years) with stage III to IV indolent B-cell lymphoma, including grades 1
Autor:
Rodrigo Ito, Toby A. Eyre, Nirav N. Shah, Steven Le Gouill, Martin Dreyling, Elisabeth Vandenberghe, Wojciech Jurczak, Yucai Wang, Chan Y. Cheah, Mitul Gandhi, Christopher Chay, Jeff Sharman, David J. Andorsky, Yuqin Song, Amy Stark, Valerie Muthig, Michael L. Wang
Publikováno v:
Clinical lymphoma, myelomaleukemia. 22
Covalent Bruton's Tyrosine Kinase (BTK) inhibitors (BTKi) have transformed the management of relapsed mantle cell lymphoma (MCL), but many patients will require additional treatment. Pirtobrutinib is a highly selective, non-covalent (reversible) BTKi
Autor:
Jonathon B. Cohen, Nirav N. Shah, Alvaro J. Alencar, James N. Gerson, Manish R. Patel, Bita Fakhri, Wojciech Jurczak, Xuan Ni Tan, Katharine L. Lewis, Timothy Fenske, Catherine C. Coombs, Ian W. Flinn, David J. Lewis, Steven Le Gouill, M. Lia Palomba, Jennifer A. Woyach, John M. Pagel, Nicole Lamanna, Minal A. Barve, Paolo Ghia, Toby A. Eyre, Pier Luigi Zinzani, Chaitra S. Ujjani, Youngil Koh, Koji Izutsu, Ewa Lech-Maranda, Constantine S. Tam, Suchitra Sundaram, Ming Yin, Binoj Nair, Donald E. Tsai, Minna Balbas, Anthony R. Mato, Chan Y. Cheah, Michael L. Wang
Publikováno v:
Clinical Lymphoma Myeloma and Leukemia. 22:S394-S395
Covalent BTK inhibitors (BTKi) have transformed the management of mantle cell lymphoma (MCL), but most patients will require additional treatment. Pirtobrutinib is a highly selective, non-covalent (reversible) BTKi that inhibits both wild-type and C4
Publikováno v:
Expert opinion on biological therapy
Introduction: Patients with relapsed or refractory diffuse large B-cell lymphoma (R/R DLBCL) require further treatment options, especially in cases that cannot tolerate stem cell transplant or cytotoxic chemotherapy. CD19 has emerged as an attractive
Publikováno v:
Hematology. 26:860-869
Immune thrombocytopenia (ITP) is a rare disease, characterized by increased platelet destruction/suboptimal platelet production, leading to thrombocytopenia and risk of severe bleeding events. Interviews with 23 physicians and 12 payors, a survey wit
Autor:
Gandhi Damaj, Deyaa Adib, Sarit Assouline, Michael Dickinson, John Radford, Gilles Salles, Anna Schmitt, Wojciech Jurczak, Jay Yang, Tycel Phillips, Franck Morschhauser, Maciej Kazmierczak, Aristeidis Chaidos, Phillip L. Campbell, Connie Lee Batlevi, Pamela McKay, Hervé Tilly, Stephen Opat, Vincent Ribrag, Jennifer Whalen, Shefali Agarwal
Publikováno v:
Lancet Oncol
Summary Background Activating mutations of EZH2, an epigenetic regulator, are present in approximately 20% of patients with follicular lymphoma. We investigated the activity and safety of tazemetostat, a first-in-class, oral EZH2 inhibitor, in patien